Furthermore, the irreversible ErbB family blocker afatinib has demonstrated promising results in a phase IIb/III trial, improving progression-free survival in lung cancer patients whose disease progressed after chemotherapy and gefitinib/erlotinib treatment [9]. This evidence concerns the gene EGFR and lung carcinoma.